COVID-19’s impact on bioanalytical labs


Lavelle A & Micheli J | Bioanalysis, 13(15), 1169 - 1171, (2021) Keywords: • bioanalysis • clinical trials • COVID-19 • NAAT • SARS-CoV-2 antigen • serology The COVID-19 pandemic has presented unique challenges to the bioanalytical community. One year later, the impact of the pandemic on business practices, supply chains, timelines and project prioritization have been felt across the industry. Due to travel and personnel restrictions, laboratories have adapted their day to day lab operations and clinical trial practices. Logistically, supply chains have been affected, resulting in reduced availability of lab consumables, reagents, personal protective equipment (PPE) and biological...

To view this content, please register now for access

It's completely free